KR20210034055A - Htlv-1 관련 척수증(ham) 치료 또는 예방제, 및 ham의 치료 방법 - Google Patents
Htlv-1 관련 척수증(ham) 치료 또는 예방제, 및 ham의 치료 방법 Download PDFInfo
- Publication number
- KR20210034055A KR20210034055A KR1020217005032A KR20217005032A KR20210034055A KR 20210034055 A KR20210034055 A KR 20210034055A KR 1020217005032 A KR1020217005032 A KR 1020217005032A KR 20217005032 A KR20217005032 A KR 20217005032A KR 20210034055 A KR20210034055 A KR 20210034055A
- Authority
- KR
- South Korea
- Prior art keywords
- ser
- leu
- thr
- val
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018135925 | 2018-07-19 | ||
| JPJP-P-2018-135925 | 2018-07-19 | ||
| PCT/JP2019/028431 WO2020017629A1 (ja) | 2018-07-19 | 2019-07-19 | Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210034055A true KR20210034055A (ko) | 2021-03-29 |
Family
ID=69163691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217005032A Ceased KR20210034055A (ko) | 2018-07-19 | 2019-07-19 | Htlv-1 관련 척수증(ham) 치료 또는 예방제, 및 ham의 치료 방법 |
Country Status (16)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2025070749A1 (cg-RX-API-DMAC7.html) * | 2023-09-29 | 2025-04-03 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010100578A (ja) | 2008-10-24 | 2010-05-06 | St Marianna Univ School Of Medicine | Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を予測する方法 |
| KR20110071059A (ko) | 2008-09-02 | 2011-06-28 | 도레이 토넨 기노우마쿠 고도카이샤 | 미세다공성 고분자막, 이 미세다공성 고분자막의 제조방법 및 전지 세퍼레이터 필름으로서의 이 미세다공성 고분자막의 사용 |
| JP2014138599A (ja) | 2008-02-29 | 2014-07-31 | Abbott Gmbh & Co Kg | Rgmaタンパク質に対するモノクローナル抗体及びその使用 |
| JP2017526930A (ja) | 2014-09-10 | 2017-09-14 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | RGMa断片ベース診断アッセイ |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1442749A1 (en) * | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| WO2005087268A1 (ja) * | 2004-03-11 | 2005-09-22 | Bioclues, Inc | 軸索再生促進剤 |
| KR102284780B1 (ko) | 2009-12-09 | 2021-08-02 | 미쓰비시 타나베 파마 코퍼레이션 | T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법 |
| CA2824515C (en) * | 2011-01-18 | 2022-09-13 | Bioniz, Llc | Compositions and methods for modulating gamma-c-cytokine activity |
| JP5963233B2 (ja) * | 2011-12-07 | 2016-08-03 | 学校法人 聖マリアンナ医科大学 | Htlv−1関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法 |
| JP6310845B2 (ja) * | 2012-07-06 | 2018-04-11 | 学校法人 聖マリアンナ医科大学 | Htlv−1関連脊髄症患者の治療方法および治療剤 |
| CA2983898A1 (en) * | 2015-04-28 | 2016-11-03 | Mitsubishi Tanabe Pharma Corporation | Rgma binding protein and use thereof |
| WO2017189963A1 (en) * | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| TW202523689A (zh) * | 2016-06-01 | 2025-06-16 | 美商艾伯維有限公司 | 治療脊髓損傷及疼痛之方法 |
| US10772887B2 (en) * | 2016-08-03 | 2020-09-15 | Kagoshima University | Anti-HTLV-1 drug and therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) |
-
2019
- 2019-07-19 PE PE2025002847A patent/PE20260298A1/es unknown
- 2019-07-19 CN CN202310983521.2A patent/CN116850291A/zh active Pending
- 2019-07-19 WO PCT/JP2019/028431 patent/WO2020017629A1/ja not_active Ceased
- 2019-07-19 SG SG11202100561QA patent/SG11202100561QA/en unknown
- 2019-07-19 CN CN202310983220.XA patent/CN116942831A/zh active Pending
- 2019-07-19 CN CN201980048012.2A patent/CN112566664B/zh active Active
- 2019-07-19 EP EP25202154.8A patent/EP4656657A3/en active Pending
- 2019-07-19 KR KR1020217005032A patent/KR20210034055A/ko not_active Ceased
- 2019-07-19 JP JP2020531380A patent/JP7150286B2/ja active Active
- 2019-07-19 TW TW108125746A patent/TWI825131B/zh active
- 2019-07-19 TW TW112142583A patent/TW202408577A/zh unknown
- 2019-07-19 AU AU2019306721A patent/AU2019306721B2/en active Active
- 2019-07-19 PE PE2021000080A patent/PE20211376A1/es unknown
- 2019-07-19 CA CA3112511A patent/CA3112511A1/en active Pending
- 2019-07-19 MX MX2021000732A patent/MX2021000732A/es unknown
- 2019-07-19 EP EP19838340.8A patent/EP3824907B1/en active Active
- 2019-07-19 BR BR112021000949-3A patent/BR112021000949A2/pt unknown
- 2019-07-19 CN CN202310983277.XA patent/CN116785439A/zh active Pending
- 2019-07-19 US US17/261,480 patent/US20210269535A1/en active Pending
-
2021
- 2021-01-18 IL IL280257A patent/IL280257A/en unknown
- 2021-01-18 PH PH12021550134A patent/PH12021550134A1/en unknown
- 2021-02-18 ZA ZA2021/01113A patent/ZA202101113B/en unknown
-
2022
- 2022-09-16 JP JP2022148180A patent/JP7475011B2/ja active Active
-
2024
- 2024-04-08 JP JP2024061895A patent/JP7703174B2/ja active Active
-
2025
- 2025-06-16 JP JP2025100449A patent/JP2025134820A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014138599A (ja) | 2008-02-29 | 2014-07-31 | Abbott Gmbh & Co Kg | Rgmaタンパク質に対するモノクローナル抗体及びその使用 |
| JP2016175897A (ja) | 2008-02-29 | 2016-10-06 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | Rgm aタンパク質に対するモノクローナル抗体及びその使用 |
| KR20110071059A (ko) | 2008-09-02 | 2011-06-28 | 도레이 토넨 기노우마쿠 고도카이샤 | 미세다공성 고분자막, 이 미세다공성 고분자막의 제조방법 및 전지 세퍼레이터 필름으로서의 이 미세다공성 고분자막의 사용 |
| JP2010100578A (ja) | 2008-10-24 | 2010-05-06 | St Marianna Univ School Of Medicine | Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を予測する方法 |
| JP2017526930A (ja) | 2014-09-10 | 2017-09-14 | アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー | RGMa断片ベース診断アッセイ |
Non-Patent Citations (1)
| Title |
|---|
| N Engl J Med, 2018, 378, 529-538. |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102291971B1 (ko) | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 | |
| KR102223464B1 (ko) | T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법 | |
| JP5552630B2 (ja) | Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法 | |
| JP2025134820A (ja) | Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法 | |
| CA2824313A1 (en) | Tlr3 binding agents | |
| RU2833547C2 (ru) | Терапевтический или профилактический агент для htlv-1-ассоциированной миелопатии (ham) и способ лечения ham | |
| KR20230154239A (ko) | 항체-매개 이식 거부의 치료에 사용하기 위한 항-cd38 항체 | |
| CN114616245A (zh) | 一种抗cd38的抗体及其用途 | |
| HK40054121A (en) | Agent for treatment or prevention of htlv-1-associated myelopathy (ham), and ham treatment method | |
| US20250154238A1 (en) | Methods and compositions for treating and preventing fibrosis | |
| JP2025118705A (ja) | 末梢神経再生を促進するためのcxcl13結合分子の使用 | |
| WO2021085295A1 (ja) | 免疫応答抑制剤 | |
| CN116997570A (zh) | 用于治疗抗体介导的移植排斥的抗cd38抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |